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Abstract
C5-substituted 2,4-diaminoquinazolines (2,4-DAQs) ameliorate disease severity in SMA
mice. It is uncertain, however, that these compounds increase SMN protein levels in vivo
even though they were identified as activators of the SMN2 promoter. These compounds
also regulate the expression of other transcripts in neuroblastoma cells. In this study, we
investigate the mechanism by which the 2,4-DAQs regulate the expression of SMN2 as well
as other targets. D156844, D158872, D157161 and D157495 (RG3039) increased SMN2
promoter-driven reporter gene activity by at least 3-fold in NSC-34 cells. These compounds,
however, did not significantly increase SMN2 mRNA levels in type II SMA fibroblasts nor in
NSC-34 cells, although there was a trend for these compounds increasing SMN protein in
SMA fibroblasts. The number of SMN-containing gems was increased in SMA fibroblasts in
response to 2,4-DAQ treatment in a dose-dependent manner. ATOH7 mRNA levels were
significantly lower in type II SMA fibroblasts. 2,4-DAQs significantly increased ATOH7,
DRNT1 and DRTN2 transcript levels in type II SMA fibroblasts and restored ATOH7 levels
to those observed in healthy fibroblasts. These compounds also increase Atoh7 mRNA
expression in NSC-34 cells. In conclusion, 2,4-DAQs regulate SMN2 by increasing protein
levels and gem localization. They also increase ATOH7, DRNT1 and DRNT2 transcript lev-
els. This study reveals that the protective effects of 2,4-DAQs in SMA may be independent
of SMN2 gene regulation. These compounds could be used in concert with a proven SMN2
inducer to develop a multi-faceted approach to treating SMA.
Introduction
Proximal spinal muscular atrophy (SMA) is an early-onset neurodegenerative disease charac-
terized by the loss of α-motor neurons in the anterior horn of the spinal cord which leads to
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muscle weakness and atrophy [1;2]. SMA is an autosomal recessive disease that is a leading
genetic cause of infant death worldwide with an incidence of 1 in ~10,000 births [3;4]. SMA
can be classified into five clinical grades based on age of onset and the highest achieved motor
milestone. Regardless of clinical grade, proximal SMA results from the loss or mutation of
SMN1 (survival motor neuron 1) on chromosome 5q13 [5]. SMN protein is involved the assem-
bly of small nuclear ribonucleoprotein (snRNP) complexes required for splicing [2]. SMN is
also implicated in stabilizing messenger ribonucleoprotein (mRNP) complexes in axons [6]. In
addition to these well characterized functions, SMN is involved in many other intracellular
processes [7].
In humans a large tandem chromosomal duplication has lead to a second copy of this gene
known as SMN2 [8;9]. SMN2 is functionally distinguishable from SMN1 by a single nucleotide
difference (SMN2 c.850C>T) in exon 7 that disrupts an exonic splice enhancer. As a result,
most SMN2 mRNAs lack exon 7 (SMNΔ7) and produce a protein that is both unstable and less
than fully functional [10–12]. Although only 10–20% of the SMN2 gene product is fully func-
tional [8;9], increased genomic copies of SMN2 inversely correlates with disease severity
among individuals with SMA [13]. Studies using transgenic mouse models for SMA have
shown that increased SMN2 copy number lessens the phenotypic severity of disease [14–16].
SMN2 copy number variation, therefore, is a major modifier of disease severity in SMA.
As SMN2 is a major genetic modifier of SMA phenotype, it has become the primary target
for the development of therapies—both small molecular and biological—for SMA. Numerous
studies have identified many classes of compounds as inducers of SMN2 expression [17]. Small
molecule drugs can increase SMN2 expression in vivo at different levels of gene regulation,
such as enhancing promoter activity or increasing the inclusion of exon 7 in SMN2 mRNA
transcripts. C5-substituted 2,4-diaminoquinazolines (2,4-DAQs) are potent inducers of SMN2
promoter activity that were identified through a high-throughput drug screen [18]. The piperi-
dine derivative D156844 increases SMN expression in type II SMA fibroblasts and ameliorates
the survival and phenotype of SMNΔ7 SMA mice [19–22]. RG3039, also known as D157495,
increases the mean lifespan in multiple mouse models of SMA [23;24].
The 2,4-DAQs bind to and inhibit the activity of the mRNA decapping enzyme DcpS [25].
DcpS is a member of the histidine triad family of nucleotide hydrolases and is implicated in
mRNA degradation [26]. After complete 3’ to 5’ degradation of the mRNA in eukaryotes by
exonucleases, DcpS hydrolyzes the residual cap structure, 7-methylguanosine nucleoside tri-
phosphate (m7GpppN), to release 5’ diphosphate-oligonucleotide mRNA and 7-methylguano-
sine monophosphate (m7GMP) as products [26;27]. DcpS is also implicated in the 5’ to 3’
mRNA decay pathway where it is found to dephosphorylate the m7GDP decapping product to
m7GMP [28]. It is unclear how DcpS inhibition by the 2,4-DAQs increases SMN2 expression.
In this study, we examined the effects of a novel group of 2,4-DAQs on the regulation of SMN2
expression in type II SMA fibroblast lines as well as in motor neuron-based reporter cell lines.
We also examined the effects of these 2,4-DAQs on the expression of three DcpS-regulated
transcripts [29]—ATOH7 (atonal homologue 7), DRNT1 (DcpS-responsive noncoding transcript
1) and DRNT2—in type II SMA fibroblasts.
Materials and methods
Drug compounds
The C5-substituted 2,4-diaminoquinazoline derivatives D156844, D157495 (RG3039),
D157161 and D158872 were obtained from Repligen Corp. (Waltham, MA) and were all dis-
solved in DMSO.
2,4-DAQ-mediated gene regulation in SMA
PLOS ONE | https://doi.org/10.1371/journal.pone.0180657 June 29, 2017 2 / 22
Cell culture
Fibroblasts derived from type II SMA (GM03813, GM22592 and AIDHC-SP22) and non-
SMA (GM03814, AIDHC-NMC1, AIDHC-SC1 and AIDHC-SC2) individuals were grown in
DMEM containing 10% EquaFETAL (Atlas Biologicals, Fort Collins, CO), 2 mM L-glutamine
(Life Technologies, Grand Island, NY) and 1% penicillin-streptomycin (Life Technologies).
GM03813 [30], GM22592 and GM03814 [30] fibroblast lines were obtained from Coriell Cell
Repositories (Camden, NJ) while the other fibroblast lines were generated at Nemours/Alfred
I. duPont Hospital for Children. All type II SMA fibroblast lines used in this study contain 0
copies of SMN1 and 3 copies of SMN2 [31]. GM03814 fibroblasts [30] were derived from the
carrier mother of GM03813 and contain 1 copy of SMN1 and 5 copies of SMN2 [31]. The
other non-SMA fibroblast lines contain 2 copies of SMN1 and 2 copies of SMN2 [31]. The
fibroblast lines were authenticated using short tandem repeat profiling and digital PCR as
described previously [32].
The mouse motor neuron cell line NSC-34 [33] and the NSC-34-based reporter lines
[18;34] were maintained in DMEM, 5% EquaFETAL, 2 mM L-glutamine and 1% penicillin/
streptomycin. In all instances, the cells were maintained in a humidified chamber at 37˚C and
5% CO2.
β-Lactamase reporter assays
The clone 11 cell line (Vertex Pharmaceuticals, [18]) was used for the SMN2 promoter assay
and the clone 5.3 (Vertex Pharmaceuticals, [34]) was used for the SMN2 splicing assay. The
cells were seeded onto a black-walled, clear bottom 96-well tissue culture plates (Santa Cruz
Biotechnology) at a density of 5×104 cells/well. For these experiments, the compounds were
tested in quadruplicate. Drug compounds were added to the medium using a 96-pin replicator
(pin diameter = 1.19 mm; V&P Scientific, Inc., San Diego, CA) and plates were incubated for
19 hours. At the end of the incubation, 20μL of 6X CCF2-AM dye (GeneBlazer In Vivo Detec-
tion Kit, Life Technologies) was added to each of the assay wells and plates were incubated at
room temperature for 2 hours before the plates are read on a plate reader (Victor X4, Perkin
Elmer). Fluorescence intensities (F) were obtained at 2 wavelengths for each sample: the
CCF2-AM substrate at λem = 530 nm and the cleaved product at λem = 460 nm. The normal-
ized fluorescence intensity ratio (F460:F530) was plotted against compound concentration and
used to generate a dose response curve for the SMN2 promoter assay.
Treatment of cells with 2,4-DAQs
All cells were plated 24 hours prior to treatment with drug compounds and harvested by scrap-
ing following five days of treatment. This treatment paradigm was selected to monitor changes
in response to chronic exposure to these compounds, which would be similar to conditions
observed in SMA patients treated with one of these compounds. Medium was changed daily
and fresh drug compounds or DMSO was added at a 1:1000 dilution every 24 ± 2 hours during
the five-day treatment period.
Immunofluorescence and gem count analysis
For immunofluorescence, cells were seeded onto gelatinized glass coverslips at a density of
4000 cells/cm2 and treated with compounds as described above. Immunostaining of fibroblast
cells was accomplished as described previously [19;35] using the MANSMA2 mouse anti-SMN
mAb (1:200; Developmental Studies Hybridoma Bank, Iowa City, IA [36]). SMN immunos-
taining within the nuclei of treated fibroblasts was visualized using a DMRXA2 epifluorescence
2,4-DAQ-mediated gene regulation in SMA
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microscope (Leica Microsystems) with an ORCA-ER cooled camera (Hamamatsu, Hamama-
tsu City, Japan) and Volocity 6.1.1 software (Perkin-Elmer). Gems were counted 10 randomly
selected nuclei in a field of view; this process was repeated for a total of 10 randomly selected,
non-overlapping fields of view. The following parameters were measured: the number of
gems, the number of cells with gems and the number of cells with more than 1 gem.
Quantitative RT-PCR
Cells were seeded onto 6-well plates at a density of 3.2×104 cells/well and treated as described
above. The total RNA was extracted from cell lines using the RNAeasy Mini columns (QIA-
GEN, Germantown, MD), according to the manufacturer’s recommendations. First-strand
complementary DNA was carried out using the iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA) according to manufacturer’s directions. Quantitative PCR was performed in a 384 well
plate on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Target
transcripts were amplified by real time polymerase chain reaction using the SYBR Green PCR
Master Mix (QIAGEN) in 10 μL total volume and the following cycling conditions: a 10-min-
ute initial denaturation step at 95˚C, followed by 40 cycles of 15 seconds at 95˚C and 1 minute
at 60˚C. All samples were assayed in triplicate. The following primer sets (Integrated DNA
Technologies, Coralville, IA) were used: ATOH7 [29], (F) 5’-AAAGCTGTCCAAGTACGAG
AC-3’, (R) 5’-CGAAGTGCTCACAGTGGAG-3’;DRNT1 [29], (F) 5’-CACCTAGACTCATC
ACTTAGATCCACC-3’, (R) 5’-GAGACCTGATGGCTACAACTGACA-3’;DRNT2 [29], (F)
5’-TGGAGAAGCGATGGATGACAGAGA-3’, (R) 5’-GGTGAACGGACACAATTGCCAGAA-
3’; PAQR8 [29], (F) 5’-AACGTCTGGACCCATTTACTG-3’, (R) 5’-CAGGTGAGGTAAGT-
GATTGAC-3’; SMNex6Fq, 5’-CCATATGTCCAGATTCTCTTGATGA-3’; SMNex78Rq, 5’-A
TGCCAGCATTTCTCCTTAATTTA-3’; SMNex68Rq, 5’-ATGCCAGCATTTCCATATAATAG
C-3’; Smn, (F) 5’-AGAATGCCACAACTCCCTTG-3’, (R) 5’-ATCCAGTATAAACCACGAC
ACAG-3’ and Atoh7, (F) 5’-CAAGCTCTCCAAGTACGAGAC-3’, (R) 5’-TCTACCTGGAG
CCTAGCAC-3’. For the fibroblast samples, data for each transcript were normalized to the
geometric mean of three reference transcripts, ACTB (β-actin), GAPD (glyceraldehyde 3-phos-
phate dehydrogenase), and RPLP0 (ribosomal protein lateral stalk subunit P0), to minimize the
variability in the expression of a single reference [37]. The data for each NSC-34 sample were
normalized to the geometric mean of Rpl13a (ribosomal protein L13a) and Pgk (phosphoglycer-
ate kinase). The reference primer sets were obtained from RealTime Primers LLC (Elkins
Park, PA). The relative transcript levels were calculated using the efficiency-adjusted 2-ΔΔCt
method [38;39]. The PCR efficiency (E) for each primer set was calculated from the slope of a
Ct vs. log10(cDNA serial dilution) curve (E = 10[-1/slope]) [40]. ΔCt,adjusted is the difference
between the adjusted Ct (Ct,measured × E) for the target transcript and the geometric mean of
the adjusted Ct values for the three reference genes and ΔΔCt is defined as the difference
between the ΔCt for the SMA sample and the ΔCt for the control sample.
mRNA stability assay
mRNA stability was assayed as described previously with modification [41]. Fibroblasts were
seeded onto 6-well plates at a density of 3.2×104 cells/well and treated with compounds or
DMSO as previously described. Twenty-four hours after the final treatment, cells were exposed
to 5 μg/mL actinomycin D (ActD; Sigma-Aldrich, St. Louis, MO) for 0, 2, 6, 12 or 24 hours.
RNA isolation and first strand complementary DNA synthesis were performed as already
described. The thermocycling profile was 50˚C for 2 minutes, 95˚C for 10 minutes, followed
by 30 cycles at 95˚C for 15 seconds and 60˚C for 1 minute, and a final cycle at 72˚C for 5 min-
utes. PCR was performed using primers specific for sequences within SMN exons 6 and 8:
2,4-DAQ-mediated gene regulation in SMA
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SMN exon 6 (F), 5’-CCCATATGTCCAGATTCTCTTGAT-3’; SMN exon 8 (R), 5’-CTACAA
CACCCTTCTCACAG-3’.COL3A (collagen IIIA) was used as control because of its high
expression in fibroblasts [41]: COL3A (F), 5’-GCTCTGCTTCATCCCACTATT-3’; COL3A
(R), 5’-GGAATACCAGGGTCACCATTT-3’. The PCR products were electrophoresed through
a 2% agarose gel. Gel images were captured with an AlphaImager system (ProteinSimple, San
Jose, CA) and band intensities were quantified using AlphaView, version 3.2.2.
Immunoblot
For protein analysis, cells were plated onto 10-cm dishes at a density of 4.0×105 cells/dish and
treated with test compounds as previously described. The resultant cell pellets were lysed in
50 μL cell lysis buffer (0.1% Triton X-100 and Complete protease inhibitor cocktail (Roche Life
Sciences, Indianapolis, IN) in phosphate-buffered saline (PBS, pH 7.4)). Lysates were sonicated
using a Sonic Dismembrator (Thermo Scientific). Protein quantification was performed using
the Micro BCA Protein Assay kit (Fisher Scientific). NSC-34 (5 μg/lane) or 10 μg fibroblast
(10 μg/lane) extracts were mixed with 0.2-volumes non-reducing 6× loading dye (10.28% SDS,
36% glycerol and 0.012% bromophenol blue in 350 mM Tris-HCl, pH 6.8) and 0.1-volumes 1
M DTT, were heated at 90˚C-100˚C for 10 minutes and briefly centrifuged. Prepared samples
along with Kaleidoscope Precision Plus protein ladder (Bio-Rad) were resolved through 12%
Polyacrylamide Mini-PROTEAN TGX Precast gels (Bio-Rad) using the Mini-PROTEAN sys-
tem (Bio-Rad). Samples were then transferred onto polyvinylidine fluoride (PVDF) mem-
branes (0.45 μm, GE Healthcare Life Sciences, Piscataway, NJ) using the Trans-Blot semi dry
transfer cell (Bio-Rad) and incubated for 1 h at room temperature in 1×blocking buffer (PBS
containing 5% milk and 0.1% Tween-20). Blots were then incubated in primary antibody solu-
tion (in 0.2×blocking buffer) overnight at 4˚C. The following primary antibodies were used:
mouse anti-SMN mAb (MANSMA2 (8F7), Developmental Studies Hybridoma Bank, Iowa
City, IA [36], 1:100), rabbit anti-ATH5 (ATOH7) pAb (EMD Millipore; 1:200), rabbit anti-
MATH5 (ATOH7) pAb (Abcam; 1:100), rabbit anti-ATOH7 pAb (Thermo Scientific; 1:1000),
rabbit anti-MATH5 (ATOH7) mAb (EPR13935, Abcam; 1:1000), mouse anti-β-actin mAb
(AC-15, Sigma-Aldrich, 1:5000) and mouse anti-β-tubulin mAb (E7, Developmental Studies
Hybridoma Bank [42], 1:100). The blots were extensively washed with PBS containing 0.1%
Tween-20 (PBST; 3×10 min) and incubated for 1 h at room temperature with an HRP-linked
anti-mouse or anti-rabbit IgG secondary antibody (1:5000; Rockland Immunochemicals, Inc.,
Pottstown, PA) diluted in 0.2×blocking buffer. After extensive washing, the bound antibody
was detected by chemiluminescence using either the Western Sure ECL Substrate (LiCor, Lin-
coln, NE) or SuperSignal West Femto (Thermo Scientific) kits and developed with the C-DiGit
Blot Scanner (LiCor). Band intensities, defined as the band signal divided by the band area,
were measured using the Image StudioTM Lite software (LiCor). The measured band areas were
the same for each sample on a blot. Band intensities for the target protein (SMN) were divided
by those for the reference protein (β-actin or β-tubulin) to obtain normalized band intensities.
To measure the relative protein level for a sample, the normalized band intensity for the drug-
treated sample was divided by the normalized band intensity for the control sample (either
DMSO-treated cells or a reference cell line).
Data and statistical analysis
Data are expressed as mean ± standard error. Parametric data were analyzed by ANOVA with
either a Bonferroni (gem analysis) or Holm-Sidak (expression analysis) post hoc test. Statistical
significance was set at p 0.05. Comparisons between data were performed with Sigma Plot
2,4-DAQ-mediated gene regulation in SMA
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v.12.0 or SPSS v.22.0. The EC50 value of each compound for the SMN2 promoter assay was
determined using Prism (GraphPad).
Results
Effects of C5-substituted 2,4-DAQs on SMN-containing gem localization
in type II SMA fibroblasts
In most cells, SMN localizes to discreet foci within the nucleus known as gems [43]. In SMA
cells, the number of subnuclear gems is greatly reduced and the magnitude of gem deficit is
related to clinical severity [44]. As the 2,4-DAQ D156844 has been previously shown to
increase the number of SMN-positive gems within the nuclei of SMA cells [19], we examined
the effects of three other C5-substituted 2,4-DAQs—D158872, D157161 and D157495—on
gem localization in GM03813 type II SMA fibroblasts. Each compound increased the number
of gems (Fig 1A) in SMA fibroblasts in a dose-dependent manner. The proportion of fibro-
blasts containing at least one subnuclear gem (Fig 1B) and more than one gem (Fig 1C) also
increased in a dose-dependent manner. At the highest doses tested (1 μM), each compound
increased the gem counts to those observed in healthy, carrier GM03814 fibroblasts.
Effects of C5-substituted 2,4-DAQs on SMN2 gene regulation
We first examined the effects of C5-substituted 2,4-DAQs on SMN2 promoter activity using
clone 11 cells. This NSC-34 clonal line contains a β-lactamase (BLA) reporter gene under the
control of a 3.4-kb fragment of the SMN2 promoter; this clonal line has been previously used
in high-throughput screening of SMN2 inducers [18]. When compared to DMSO (vehicle)-
treated cells, D156844, D158872, D157161 and D157495 significantly increased SMN2-drived
BLA activity as measured by an increase in the λ460:λ530 fluorescence emission ratio (Fig 2A).
All four compounds displayed sigmoidal dose-dependent increases in SMN2-drived BLA
activity (Fig 2B–2E). Based on EC50 values, D157495 was 2.5-fold more potent at increasing
SMN2-drived BLA activity than D156844 (Table 1). These compounds were ranked as follows
based on their potencies at inducing SMN2-drived BLA activity:
D157495 > D156844 = D158872 > D156171.
The effects of C5-substituted 2,4-DAQs on SMN mRNA levels were examined in GM03813
fibroblasts. Quantitative RT-PCR showed that the amounts of full-length SMN (FL-SMN) (Fig
3A) and exon 7 lacking SMN (SMNΔ7) (Fig 3B) did not increase in response to treatment with
D156844, D158872, D157161 or D157495. To determine whether or not these observations were
unique to this fibroblast line, we also examined the effects of the C5-substituted 2,4-DAQs on
SMN mRNA levels in two additional type II SMA fibroblast lines, GM22592 and AIDHC-SP22,
that possess the same SMN2 copy number as GM03813 cells [31]. As a control, FL-SMN and
SMNΔ7mRNA levels in response to D156844, D157161, D158872 and D157495 were measured
in three healthy fibroblast lines—AIDHC-NMC1, AIDHC-SC1 and AIDHC-SC2—that have 2
copies of SMN1 and 2 copies of SMN2 [31]. Under basal conditions, FL-SMN (Fig 3C) mRNA
levels were lower in type II SMA fibroblast lines when compared against healthy fibroblasts.
With the exception of AIDHC-NMC1, basal SMNΔ7 (Fig 3D) mRNA levels were not different
between type II SMA and healthy fibroblasts. FL-SMN (Fig 3E) or SMNΔ7 (Fig 3F) mRNA levels
were not affected by the compounds in either SMA or healthy cells. The variability in responsive-
ness to these compounds was observed in both SMA and healthy fibroblasts.
In addition to examining the effects of C5-substituted 2,4-DAQs on FL-SMN and SMNΔ7
mRNA levels, we also measured changes in the alternative splicing of SMN2 mRNAs at exon 7.
Clone 5.3 NSC-34 cells contain a BLA reporter gene whose expression is dependent on
2,4-DAQ-mediated gene regulation in SMA
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Fig 1. Effects of C5-substituted 2,4-DAQs on SMN localization to the nucleus in GM03813 type II SMA
fibroblasts. Cells were treated with different doses (10–1000 nM; n = 3/dose/drug) of D158872, D157161,
2,4-DAQ-mediated gene regulation in SMA
PLOS ONE | https://doi.org/10.1371/journal.pone.0180657 June 29, 2017 7 / 22
inclusion of exon 7 in the SMN mini-gene construct [34]. Clone 5.3 cells were treated with
1 μM D156844, D158872, D157161 and D157495 and then assayed for SMN2 exon 7 inclusion,
i.e. increased BLA activity. SMN2 exon 7 inclusion was not altered by these compounds (Fig
4A); in fact, two of the compounds, D157161 and D157495, reduced SMN2 exon 7 inclusion.
The effects of these compounds on the splicing of exon 7 were also measured in type II SMA
fibroblasts. GM03813 cells were treated with 1 μM D156844, D157161, D158872, D157495 or
DMSO for 5 days; FL-SMN and SMNΔ7 transcripts were measured by qualitative RT-PCR and
agarose electrophoresis. The proportion of FL-SMN or SMNΔ7 mRNAs in these cells were not
affected by these compounds (Fig 4B).
The effects of C5-substituted 2,4-DAQs on SMN protein levels in GM03813 fibroblasts
were measured using immunoblot. D158872, D157161 and D157495 increased SMN protein
levels in treated GM03813 cells (Fig 5A and 5B). SMN protein levels in cells, however, were
not affected by treatment with D156844. SMN protein levels were increased in GM33592 type
II SMA and AIDHC-NMC1 healthy fibroblasts (Fig 5C and 5D). Some variability in respon-
siveness to 2,4-DAQs was observed between cell lines.
Effects of C5-substituted 2,4-DAQs on SMN2 mRNA stability
C5-substituted 2,4-DAQs act as inhibitors of the mRNA decapping enzyme DcpS [25]. Since
DcpS activity is required for mRNA degradation [45], these compounds may stabilize FL-SMN
and SMNΔ7 transcripts thereby increasing SMN protein levels in SMA cells. To test this hypoth-
esis, GM03813 and GM03814 fibroblasts were treated with D156844 and D157495 for 5 days
and then exposed to the transcriptional inhibitor ActD for up to 24 hours. The degradation of
FL-SMN and SMNΔ7 mRNAs were monitored by RT-PCR and agarose gel electrophoresis; col-
lagen IIIA (COL3A) mRNA degradation was also monitored as a control [41]. Qualitatively,
D156844 and D157495 increase FL-SMN and SMNΔ7 transcripts in GM03813 fibroblasts after
12 h exposure to ActD (Fig 6A). Neither treatment with D156844 or D157495, however, affected
the rates of degradation for FL-SMN or SMNΔ7 mRNAs either in GM03813 (Fig 6B and 6C) or
in GM03814 (Fig 6D and 6E) cells. These compounds, therefore, do not affect SMN2 mRNA
stability in fibroblasts.
Effects of C5-substituted 2,4-DAQs on DcpS-responsive transcripts in
SMA fibroblasts
We measured the effects of the 2,4-DAQs on the levels of DcpS regulated transcripts [29]—
ATOH7, PAQR8 (progestin/adipoQ receptor 8), RAB26,DRNT1 and DRNT2—in SMA fibro-
blasts. All of these transcripts except for RAB26were expressed in fibroblasts. GM03813 fibro-
blasts were treated with 1 μM D156844, D158872, D156171, D157495 or DMSO for 5 days. All
four compounds significantly increased ATOH7 mRNA as well as DRNT1 and DRNT2 long
noncoding RNA (lncRNA) levels in GM03813 SMA fibroblasts (Fig 7A).
Interestingly, the levels for each of the transcripts examined were lower in GM03813 fibro-
blasts when compared to healthy cells. Based on this observation, we measured ATOH7,
DRNT1 and DRNT2 transcript levels in 3 different type II SMA fibroblast lines (GM03813,
D157495 or DMSO (vehicle) for 5 days. The number of SMN-positive gems within 100 randomly selected
nuclei was counted. As a control, the number of gems in healthy, carrier fibroblasts (GM03814) was also
measured. The gem count analysis was expressed as (A) the number of gems per 100 nuclei, (B) the
proportion of cells containing gems and (C) the proportion of cells containing multiple gems. The dashed line
represents the value for DMSO-treated GM03813 fibroblasts. The asterisk (*) denotes a statistically
significant (p 0.05) difference between drug- and vehicle-treated cells.
https://doi.org/10.1371/journal.pone.0180657.g001
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Fig 2. Effects of C5-substituted 2,4-DAQs on SMN2-drived BLA activity. Clone 11 NSC-34 cells harboring a reporter gene driven by the 3.4-kb
SMN2 promoter were treated with 1 μM D156844, D158872, D157161, D157495 or DMSO (n = 4/drug) for 19 hours prior to fluorescent β-lactamase
assay analysis. (A) All 4 compounds significantly increased SMN2-drived BLA activity. The asterisk (*) denotes a statistically significant (p 0.05)
difference between drug- and vehicle-treated cells. Dose-response curves (1 nM– 10 μM) for D156844 (B), D158872 (C), D157161 (D) and D157495
(E). Each compound tested exhibited a dose-dependent increase in SMN2-drived BLA activity.
https://doi.org/10.1371/journal.pone.0180657.g002
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GM22592 and AIDHC-SP22) relative to 3 different healthy fibroblast lines (AIDHC-NMC1,
AIDHC-SC1 and AIDHC-SC2). ATOH7 mRNA levels were lower in the 3 type II SMA fibro-
blasts tested when compared against the 3 non-SMA fibroblasts used in this study (Fig 7B). In
contrast, the levels of DRNT1 (Fig 7C) and DRNT2 (Fig 7D) lncRNAs were not significantly
different between SMA and non-SMA fibroblasts although there was a trend for reduced levels
of these transcripts in type II SMA fibroblasts. The inductive effects of all four 2,4-DAQs on
ATOH7 (Fig 7E) mRNA as well as DRNT1 (Fig 7F) and DRNT2 (Fig 7G) lncRNA expression
were observed in both type II SMA and non-SMA fibroblasts.
The changes in ATOH7 protein levels were measured by immunoblot. Unfortunately, we
could not detect a protein band with the appropriate size (17 kDa) in fibroblast samples using
4 different antibodies directed against ATOH7 (data not shown). We were able to detect bands
at ~34 kDa and ~50 kDa but it was unclear if these bands were specific to ATOH7. This obser-
vation has been made in other studies involving ATOH7 protein expression [46].
Effects of C5-substituted 2,4-DAQs on Smn and Atoh7 expression in
NSC-34 cells
The lack of effect of the 2,4-DAQs on SMN2 gene regulation in SMA fibroblasts may be due to
the cell type assayed since SMN2 promoter activity was monitored in motor neuron-like NSC-34
cells and not in fibroblasts. To address this possibility, we examined the effects of the 2,4-DAQs
on the expression of the murine SMN gene (Smn) in NSC-34 cells. Smn mRNA levels were not
affected by treatment of NSC-34 cells with D156844, D158872, D157161 or D157495 for 5 days
(Fig 8A). Smn protein levels were not affected by these compounds in NSC-34 cells (Fig 8B and
8C).
We also determined the effect of the 2,4-DAQs on Atoh7 expression in a motor neuron
environment. Atoh7 mRNA levels were increased by 2.5–3.0 fold in treated NSC-34 cells (Fig
8D). Atoh7 protein levels, however, could not be measured due to the lack of a specific anti-
body against this antigen.
Discussion
SMN2 is an endogenous genetic modifier of SMA disease severity [13]. Many SMA therapeu-
tics discovery programs aim to increase the amount of SMN protein from SMN2 by exploring
multiple mechanisms including increasing transcription from the SMN2 promoter, enhancing
the inclusion of exon 7 in the SMN2 mRNA or stabilizing SMNΔ7 protein [17]. Initially identi-
fied from an ultrahigh throughput drug screen [18], C5-substituted 2,4-DAQs activate SMN2
promoter activity and also increase SMN localization to subnuclear gems in SMA patient
fibroblasts [19]. D156844 and D157495 (RG3039) have been shown to improve motor neuron
function and extend survival of SMA mice models [20–24]. In this study, we examined the
Table 1. EC50s of the C5-substituted 2,4-DAQs on SMN2-drived BLA activity.
compound mean EC50 (nM) R2
D156844 58.36 ± 0.0075 0.9923
D158872 54.59 ± 0.017 0.9991
D157161 77.17 ± 0.014 0.0991
D157495 23.30 ± 0.0042 0.9744
The effects of the C5-substituted 2,4-DAQs on the activity of BLA driven by the 3.4-kb SMN2 promoter were
measured in clone 11 reporter cells. Each calculated EC50 was expressed as the mean ± SEM (n = 4).
https://doi.org/10.1371/journal.pone.0180657.t001
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Fig 3. Effects of C5-substituted 2,4-DAQs on expression of full-length SMN (FL-SMN) and SMNΔ7 mRNA levels in
fibroblasts. Fibroblasts were treated with 1–1000 nM D156844, D158872, D157161, D157495 or DMSO for 5 days. mRNA levels of
FL-SMN and SMNΔ7 were measured via quantitative RT-PCR with ACTB, GAPD and RPLP0 being used as reference transcripts.
The levels of either FL-SMN (A) or SMNΔ7 (B) mRNAs were not affected by the compounds in GM03813 fibroblasts. All transcript
levels were expressed relative to DMSO-treated, GM03813 cells (dashed line). The basal levels of FL-SMN (C) and SMNΔ7 (D)
mRNAs were measured in 3 different type II SMA (GM03813, GM22592 and AIDHC-SP22) and non-SMA (AIDHC-NMC1,
AIDHC-SC1 and AIDHC-SC2) fibroblast lines. All transcript levels were expressed relative to GM03813 cells (dashed line). These
fibroblast lines were subsequently treated for 5 days with 1 μM D156844, D158872, D157161, D157495 or DMSO. An increase in
either FL-SMN (E) or SMNΔ7 (F) mRNA levels was not observed in any cell line treated with these C5-substituted 2,4-DAQs. All
transcript levels were expressed relative to DMSO-treated cells for each fibroblast line (dashed line).
https://doi.org/10.1371/journal.pone.0180657.g003
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effects of four 2,4-DAQs—D156844, D158872, D157161 and D157495—on different levels of
SMN2 gene regulation. Our results show that these compounds increased reporter gene activ-
ity which is driven by a 3.4-kb fragment of the SMN2 promoter by least 3-fold in the motor
neuron-like NSC-34 cell line, with D157495 being the most potent inducer. Surprisingly, these
compounds had no detectable effects on SMN2 mRNA levels in type II SMA fibroblasts but
they tended to increase SMN protein levels in these cells.
How can we explain the fact that 2,4-DAQs activate the SMN2 promoter but fail to increase
SMN2 mRNA levels? Stabilization of the β-lactamase transcripts caused by inhibition of DcpS
may cause an apparent 2,4-DAQ-induced increase in promoter activity in the clone 11 cell
line. This scenario, however, is unlikely because there was no increase in β-lactamase activity
Fig 4. Effects of C5-substituted 2,4-DAQs on alternative splicing of SMN2 mRNAs. (A) Clone 5.3 NSC-
34 cells harbor a reporter gene whose expression is linked to inclusion of SMN2 exon 7. These cells were
treated with 1 μM D156844, D158872, D157161, D157495 or DMSO (n = 4/drug) for 19 hours prior to
fluorescent β-lactamase assay analysis. These compounds tested did not increase the inclusion of SMN2
exon 7 but D157161 and D157495 actually decreased SMN2 exon 7 inclusion. The asterisk (*) denotes a
statistically significant (p 0.05) difference between drug- and vehicle-treated cells. (B) Qualitative analysis
of the effects of D156844, D157161, D158872 and D157495 on SMN2 transcripts in type II SMA fibroblasts.
GM03813 cells were treated with 1 μM each compound or DMSO (n = 3/compound) for 5 days and then
analyzed for changes in the amounts of FL-SMN and SMNΔ7 transcripts by RT-PCR and agarose gel
electrophoresis. The amounts of FL-SMN and SMNΔ7 transcripts were also compared against GM03814
samples. COL3A transcripts were also assayed as a loading control for RT-PCR. These compounds tested
did not affect the proportion of FL-SMN relative to SMNΔ7.
https://doi.org/10.1371/journal.pone.0180657.g004
2,4-DAQ-mediated gene regulation in SMA
PLOS ONE | https://doi.org/10.1371/journal.pone.0180657 June 29, 2017 12 / 22
in clone 5.3 cells—which are used as an indicator of SMN2 exon 7 inclusion [34]—in response
to 2,4-DAQ treatment. Another possibility for these disparate results may be that the effects of
the 2,4-DAQs on SMN2 expression are specific to either cell-type or species. The promoter
reporter assay is housed in NSC-34 cells, which are a fusion between mouse motor neurons
and neuroblastoma [33;47], while the SMN2 expression studies were completed in type II
SMA fibroblasts. We did not observe any changes in Smn mRNA or protein levels in NSC-34
cells treated with 2,4-DAQs suggesting that the cell-type specificity does not explain these dis-
parate findings. The promoter assay used in this study contains a 3.4-kb fragment of the SMN2
promoter [18]. This promoter fragment contains all the regulatory elements that facilitate
SMN2 gene transcription [48;49]. One limitation of this SMN2 promoter assay is that it does
not take into account distal regulatory elements that regulate SMN2 expression. As a result, a
given compound, like a 2,4-DAQ, may elicit a positive response with a fragment of the SMN2
promoter but not increase SMN2 expression in the context of the entire SMN2 gene.
Fig 5. Effects of C5-substituted 2,4-DAQs on SMN protein levels in fibroblasts. (A) Representative SMN and β-
actin immunoblots of GM03813 type II SMA fibroblasts treated for 5 days with 1–1000 nM D156844, D158872,
D157161, D157495 or DMSO. (B) Relative SMN protein levels—expressed as the ratio between SMN and β-actin band
intensities—in GM03813 fibroblasts treated with 2,4-DAQs. All SMN protein levels were expressed relative to DMSO-
treated GM03813 fibroblasts. (C) Representative SMN and β-actin immunoblots of type II SMA and non-SMA
fibroblasts treated for 5 days with 1 μM D156844, D158872, D157161, D157495 or DMSO. (D) Relative SMN protein
levels in type II SMA and non-SMA fibroblasts treated with 1 μM 2,4-DAQs. All SMN protein levels were expressed
relative to DMSO-treated cells for each fibroblast line (dashed line). The asterisk (*) denotes a statistically significant
(p 0.05) difference between drug- and DMSO-treated cells.
https://doi.org/10.1371/journal.pone.0180657.g005
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Fig 6. Effects of C5-substituted 2,4-DAQs on the stabilities of FL-SMN and SMNΔ7 mRNAs in fibroblasts. FL-SMN and SMNΔ7 mRNA
stabilities were measured in fibroblasts pre-treated for 5 days with either 1 μM D156844, 1 μM D157495 or DMSO and then exposed to 5 μg/mL
actinomycin D (ActD) for 0–24 hours. FL-SMN, SMNΔ7 and COL3A—a positive control for mRNA degradation—mRNAs were detected by
qualitative RT-PCR and agarose electrophoresis. (A) Qualitative analysis of SMN and COL3A transcript stabilities from GM03813 and GM03814
fibroblasts treated with D156844, D157495 or DMSO prior to ActD exposure. Stability of FL-SMN (B, D) and SMNΔ7 (C,E) mRNAs over time in
GM03813 (B,C) or GM03814 fibroblasts treated with D156844 (solid circle and solid line), D157495 (open circle and dotted line) or DMSO (closed
triangle and dashed line).
https://doi.org/10.1371/journal.pone.0180657.g006
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Fig 7. Effects of C5-substituted 2,4-DAQs on the mRNA expression of DcpS regulated transcripts. (A)
GM03813 fibroblasts were treated with 1 μM D156844, D158872, D157161, D157495 or DMSO for 5 days.
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The 2,4-DAQs did increase the number of SMN-containing gems in SMA fibroblasts in a
dose-dependent manner even though these compounds did not increase SMN2 mRNA or pro-
tein levels. These compounds may regulate the trafficking of SMN from the cytosol into the
nucleus where it forms gems. This altered subnuclear localization of SMN may result from the
induction of 2,4-DAQ-regulated genes such as ATOH7, DRNT1 or DRNT2. Future work will
investigate the regulation of SMN localization within the nucleus by the 2,4-DAQs and the
importance of 2,4-DAQ-regulated genes in this process.
The 2,4-DAQs bind to and inhibit the activity of the human mRNA scavenger decapping
enzyme DcpS [25]. This enzyme functions at multiple levels in the regulation of gene expres-
sion. DcpS cleaves the cap structures resulting from exosome degradation of mRNAs [26]. By
inhibiting DcpS, the 2,4-DAQs cause the accumulation of the m7GpppN cap structure [25]
which can sequester the nuclear cap binding protein and decrease the efficiency of first intron
removal [50]. This results in a dysfunction in translation and the normal processing of
mRNAs.
In addition to adversely affecting mRNA processing, DcpS inhibition affects the transcrip-
tional gene regulation of certain transcripts. In SH-SY5Y neuroblastoma cells, DcpS knockout
or treatment with D157495 increased the mRNA levels of ATOH7 as well as the putative
lncRNAs DRNT1 and DRNT2 [29]. We found that type II SMA fibroblasts have significantly
lower levels of ATOH7 than healthy fibroblasts; DRNT1 and DRNT2 transcript levels tended to
be lower in SMA fibroblasts but the differences were not statistically significant. Interestingly,
treatment of type II SMA fibroblasts with 2,4-DAQs restored ATOH7 mRNA expression to
levels observed in non-SMA fibroblasts. ATOH7, a single exon gene, encodes a basic helix-
loop-helix (bHLH) transcription factor that is homologous to Drosophila proneural gene
atonal [51]. Atoh7, also known as Math5 in mice, is strongly expressed in the embryonic retina
and the tenth cervical ganglion [51;52]. Atoh7 is also expressed in other regions of the nervous
system like the cochlear nucleus [53] as well as in motor neuron-like NSC-34 cells (this study).
Mutations in ATOH7 or in its promoter result in a myriad of optic disorders including optic
nerve hypoplasia, persistent hyperplasia of the primary vitreous and primary open angle glau-
coma [54–61]. ATOH7 is required for optic nerve and ganglion cell development in a context-
dependent manner and plays a key role in ocular embryogenesis [62–65]. Retinal neurons
show deficits in neurite outgrowth in a mouse model for Smn deficiency (Smn2B/- mice) [66].
The inhibited retinal neuritogenesis in Smn deficient mice may result from reduced Atoh7
expression. Future studies will determine the importance of Atoh7 in the development of SMA
retinae. The pathogenesis of SMA may also involve the optic system, which needs to be further
explored.
mRNA levels of ATOH7, DRNT1, DRNT2 and PAQR8 were measured via quantitative RT-PCR with ACTB,
GAPD and RPLP0 being used as reference transcripts. All of the 2,4-DAQs tested increased ATOH7, DRNT1
and DRNT2 transcript levels in SMA fibroblasts. All transcript levels were expressed relative to DMSO-treated,
GM03813 cells (dashed line). The asterisk (*) denotes a statistically significant (p 0.05) difference between
drug- and DMSO-treated cells. The basal levels of ATOH7 (B) mRNA as well as DRNT1 (C) and DRNT2 (D)
lncRNAs were measured in 3 different type II SMA (GM03813, GM22592 and AIDHC-SP22) and non-SMA
(AIDHC-NMC1, AIDHC-SC1 and AIDHC-SC2) fibroblast lines. ATOH7 mRNA levels were higher in non-SMA
fibroblasts than in SMA fibroblasts. Under basal conditions, DRNT1 and DRNT2 lncRNA levels are not
significantly different between type II SMA and non-SMA fibroblasts. All transcript levels were expressed relative
to GM03813 cells (dashed line). The asterisk (*) denotes a statistically significant (p 0.05) difference relative to
GM03813 fibroblasts. These fibroblast lines were separately treated for 5 days with 1 μM D156844, D158872,
D157161, D157495 or DMSO and monitored for changes in ATOH7 (E), DRNT1 (F) and DRNT2 (G) transcript
levels. Increases in ATOH7, DRNT1 and DRNT2 transcript levels were observed in all fibroblast lines treated with
these C5-substituted 2,4-DAQs. All transcript levels were expressed relative to DMSO-treated cells for each
fibroblast line (dashed line). The asterisk (*) denotes a statistically significant (p 0.05) difference between drug-
and DMSO-treated cells.
https://doi.org/10.1371/journal.pone.0180657.g007
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In summary, we found that 2,4-DAQs regulate SMN2 expression at the protein and post-
translational (i.e. gems) levels. The small increases in SMN protein resulting from 2,4-DAQ
exposure in SMA fibroblasts is consistent with previous work in SMA mice wherein these
compounds show a modest increase in SMN protein in vivo [20–24]. These compounds also
increase the abundance of ATOH7, DRNT1 and DRNT2 transcripts. These SMN2-independent
differentially expressed transcripts could be a possible neuroprotective target for SMA thera-
peutics. 2,4-DAQs have multiple neuroprotective effects on SMA that result from a modest
increase in SMN expression as well as regulation of other neuroprotective transcripts. These
compounds could be used as small molecule neuroprotectants for SMA, possibly in combina-
tion with other SMN2 inducers, since they are CNS active and has an investigational new drug
(IND) status. Examples of other SMN2 inducers include the splice switching oligonucleotide
Spinraza (nusinersen; [67–69]), which is the first FDA-approved SMA therapeutic, or the
small molecule SMN2 exon 7 splicing modifier RG7800 [70–72].
Fig 8. Effects of C5-substituted 2,4-DAQs on Smn and Atoh7 expression in NSC-34 cells. NSC-34 cells were treated
with 1 μM D156844, D158872, D157161, D157495 or DMSO for 5 days (n = 3/compound). These compounds did not affect
Smn (A) mRNA levels as measured by qRT-PCR. Treated NSC-34 cells were also measured for Smn protein levels by
immunoblot. (B) Representative SMN and β-tubulin immunoblots of NSC-34 cells treated with 1 μM D156844, D158872,
D157161, D157495 or DMSO for 5 days. (C) Relative Smn protein levels in NSC-34 cells treated with 2,4-DAQs. Smn protein
levels were not increased by these compounds in NSC-34 cells. (D) Atoh7 mRNA levels were measured in treated NSC-34
cells by qRT-PCR. All 4 compounds significantly increased Atoh7 mRNA levels in NSC-34 cells. The asterisk (*) denotes a
statistically significant (p 0.05) difference between drug- and DMSO-treated cells.
https://doi.org/10.1371/journal.pone.0180657.g008
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